PPARG and cancer: Ongoing preclinical studies are exploring additional small-molecule inhibitors of ACSL4, including rosiglitazone, a PPAR-γ agonist, which has been reported to inhibit ACSL4 in PPAR-γ, to unravel their therapeutic potential in cancer treatment [107,108].